Immuneering Corporation Operating Lease Right-of-Use Assets
Immuneering Corporation (IMRX) had Operating Lease Right-of-Use Assets of $3.14 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-05
- 2026-06-30: Operating Lease, Right-of-Use Asset $3.14M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $3.23M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $3.32M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $3.41M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $3.14M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $3.23M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $3.32M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $3.41M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $3.50M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $3.58M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $3.67M 10-K · filed 2026-03-06 |
| 2024-09-30 | $3.75M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $3.83M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $3.91M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $4.00M 10-K · filed 2025-03-20 |
| 2023-09-30 | $4.08M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.19M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $4.30M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $4.41M 10-K · filed 2024-03-01 |
| 2022-09-30 | $4.51M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $4.69M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $4.83M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $5.32M 10-K · filed 2023-03-06 |
| 2021-09-30 | $537.18K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $562.77K 10-Q · filed 2021-09-09 |
| 2020-12-31 | $613.10K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |